San Antonio—For patients with ulcerative colitis, new evidence indicates that deeper response at induction of biologic therapy, measured both histologically and endoscopically, predicts long-term benefit.
Patients who met a composite end point of histologic and endoscopic healing after completing induction “were 20% to 30% more likely to achieve a positive outcome,” such as a sustained remission at 44 weeks, than those with endoscopic healing alone, said William J. Sandborn,